53-86-1

• 常用中文名：吲哚美辛
• 常用英文名：Indometacin
• CAS号：53-86-1
• 分子式：C₁₉H₁₆ClNO₄
• 分子量：357.78800
• 相关类别： 原料药 解热镇痛药 非甾抗炎药
• 发布时间：2018-02-05 08:00:00
• 更新时间：2024-01-01 18:44:29
• Indomethacin 是一种有效的、非选择性的 COX1 和 COX2 抑制剂,在 CHO 细胞中,对人 COX-1 和 COX-2 的 IC50 值分别为 18 nM 和 26 nM。
• 为非激素类消炎镇痛药

名称

• 中文名: 吲哚美辛
• 英文名: indometacin
• 中文别名: 1-(4-氯苯甲酰基)-5-甲氧基-2-甲基-1H-吲哚-3-乙酸; 消炎痛; 1-(4-氯苯甲酰基)-5-甲氧基-2-甲基-3-吲哚乙酸; 1-对氯苯甲酰-5-甲氧基-2-甲基吲哚乙酸; 茚甲新
• 英文别名: Lausit; Catlep; Tannex; Bonidin; Indometacin; Indacin; Amuno; Inacid; 1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-3-indoleacetic Acid; EINECS 200-186-5; Dolovin; MFCD00057095; Indomethacin; INDOCIN; Vonum; 2-(1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetic acid

物化性质

• 密度: 1.32g/cm3
• 沸点: 499.4ºC at 760 mmHg
• 熔点: 155-162 °C
• 分子式: C₁₉H₁₆ClNO₄
• 分子量: 357.78800
• 闪点: 255.8ºC
• 精确质量: 357.07700
• PSA: 68.53000
• LogP: 3.92730
• 外观性状: 白色结晶粉末
• 储存条件:

  本品应密封于4℃干燥保存。

• 稳定性: Stable. Incompatible with strong oxidizing agents.
• 水溶解性: ethanol: 50 mg/mL, clear, yellow-green
• 分子结构:

  1、 摩尔折射率：94.59

  2、 摩尔体积（m³/mol）：269.5

  3、 等张比容(90.2K)：707.6

  4、 表面张力(dyne/cm)：47.4

  5、 极化率(10-24cm³)：37.49

• 计算化学:

  1.疏水参数计算参考值（XlogP）:无

  2.氢键供体数量:1

  3.氢键受体数量:4

  4.可旋转化学键数量:4

  5.互变异构体数量:无

  6.拓扑分子极性表面积68.5

  7.重原子数量:25

  8.表面电荷:0

  9.复杂度:506

  10.同位素原子数量:0

  11.确定原子立构中心数量:0

  12.不确定原子立构中心数量:0

  13.确定化学键立构中心数量:0

  14.不确定化学键立构中心数量:0

  15.共价键单元数量:1

• 更多:

  1. 性状：白色结晶。对光敏感。

  2. 密度（g/mL,25/4℃）： 未确定

  3. 相对蒸汽密度（g/mL,空气=1）：未确定

  4. 熔点（ºC）：155℃（162℃）

  5. 沸点（ºC,常压）：未确定

  6. 沸点（ºC,5.2kPa）：未确定

  7. 折射率：未确定

  8. 闪点（ºC）：未确定

  9. 比旋光度（º）： 未确定

  10. 自燃点或引燃温度（ºC）：未确定

  11. 蒸气压（kPa,25ºC）：未确定

  12. 饱和蒸气压（kPa,60ºC）：未确定

  13. 燃烧热（KJ/mol）：未确定

  14. 临界温度（ºC）：未确定

  15. 临界压力（KPa）：未确定

  16. 油水（辛醇/水）分配系数的对数值：未确定

  17. 爆炸上限（%,V/V）：未确定

  18. 爆炸下限（%,V/V）：未确定

  19. 溶解性：遇强碱分解。溶于乙醇、乙醚、丙酮和蓖麻油，几乎不溶于水。

生物活性

• 描述: Indomethacin 是一种有效的、非选择性的 COX1 和 COX2 抑制剂,在 CHO 细胞中,对人 COX-1 和 COX-2 的 IC50 值分别为 18 nM 和 26 nM。
• 相关类别:
  信号通路 >> 自噬 >> 自噬
  信号通路 >> 免疫及炎症 >> COX
  研究领域 >> 炎症/免疫
• 靶点:

  Human COX-1:18 nM (IC50, in CHO cells)

  Human COX-2:26 nM (IC50, in CHO cells)

• 体外研究: 吲哚美辛是COX1和COX2的有效非选择性抑制剂,CHO细胞中人COX-1和COX-2的IC50分别为18 nM和26 nM。吲哚美辛在人全血检测中抑制脂多糖(LPS)诱导的PGE2产生(COX-2),具有效力(IC50 = 0.68±0.17μM),并抑制凝血诱导的TXB2产生(COX-1)(IC50 = 0.19± 0.02μM)。在低花生四烯酸浓度(0.1μM)下,吲哚美辛在U937细胞微粒体中阻断COX-1,IC50为20±1 nM [1]。
• 体内研究: 吲哚美辛剂量依赖性地抑制角叉菜胶诱导的大鼠足爪水肿(ED50,2.0mg/kg),痛觉过敏(ED50,1.5mg/kg),并且对于逆转LPS诱导的大鼠发热也是有效的(ED50,1.1mg /千克)[1]。吲哚美辛(2.5mg/kg,ip)在ET-1注射后8天减少动物中NeuN +细胞的数量。吲哚美辛还可在14天时减少小胶质细胞/巨噬细胞的活化。吲哚美辛在中风后14天显着增加SVZ DCX +细胞/场的数量[2]。吲哚美辛(22.9毫克/千克,口服)产生8到10个线性粘膜病变,从胃底的幽门区延伸到幽门区[3]。
• 动物实验: 大鼠[2]为了研究吲哚美辛治疗对小胶质细胞激活，神经保护和成人神经发生的影响，将大鼠分为四个实验组：注射ET-1的动物，用无菌盐水（ip）处理7天并在8天时灌注。 ET-1注射后数天（第1组，n = 4）;注射ET-1的动物，用吲哚美辛（2.5mg / kg，ip）处理7天，并在注射ET-1后8天灌注（第2组，n = 4）;注射ET-1的动物，用无菌盐水（ip）处理7天，并在注射ET-1后14天灌注（第3组，n = 4）;注射ET-1的动物，用吲哚美辛（2.5mg / kg，ip）处理7天，并在注射ET-1后14天灌注（第4组，n = 4）。在7或14天的存活时间后，用氯胺酮盐酸盐（72mg / kg，ip）和盐酸甲苯噻嗪（9mg / kg，ip）的混合物深度麻醉动物。在验证完全没有角膜和爪抽出反射后，动物经心脏灌注肝素化0.9％温磷酸盐缓冲盐水（PBS），然后用4％冷多聚甲醛在0.1M磷酸盐缓冲液（PB），pH 7.4中灌注。将脑在相同的固定剂中后固定24小时，并在7天内在不同梯度的蔗糖 - 甘油溶液中冷冻保护。然后将组织在包埋介质中冷冻，并使用低温恒温器在冠状平面中以30μM切割。然后将切片安装在凝胶化的载玻片上并储存在-20℃的冰箱中[2]。
• 参考文献:

  [1]. Riendeau D, et al. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol. 1997 May;121(1):105-17.

  [2]. Lopes RS, et al. Indomethacin treatment reduces microglia activation and increases numbers of neuroblasts in the subventricular zone and ischaemic striatum after focal ischaemia. J Biosci. 2016 Sep;41(3):381-94.

  [3]. Afroz S, et al. Concentrated phosphatidic acid in cereal brans as potential protective agents against indomethacin-induced stomach ulcer. J Agric Food Chem. 2016 Aug 26.

  [4]. Qixiong Zhang, et al. Structure-Property Correlations of Reactive Oxygen Species-Responsive and Hydrogen Peroxide-Eliminating Materials with Anti-Oxidant and Anti-Inflammatory Activities. Chem Mater. 2017, 29(19):8221-8238.

MSDS

1.1 产品标识符 : Indomethacin 产品名称 1.2 鉴别的其他方法 无数据资料 1.3 有关的确定了的物质或混合物的用途和建议不适合的用途 仅供科研用途，不作为药物、家庭备用药或其它用途。 模块2. 危险性概述 2.1 GHS分类 急性毒性, 经口 (类别1) 2.2 GHS 标记要素，包括预防性的陈述 象形图 警示词危险 危险申明 H300吞咽致命。 警告申明 预防 P264操作后彻底清洁皮肤。 P270使用本产品时不要进食、饮水或吸烟。 措施 P301 + P310如果吞下去了: 立即呼救解毒中心或医生。 P321具体治疗(见本标签上提供的急救指导)。 P330漱口。 储存 P405存放处须加锁。 处理 P501将内容物/ 容器处理到得到批准的废物处理厂。 2.3 其它危害物 - 无 模块3. 成分/组成信息 3.1 物 质 : 357.80 g/mol 分子量 组分浓度或浓度范围 Indometacin - CAS 号53-86-1 EC-编号200-186-5 模块4. 急救措施 4.1 必要的急救措施描述 一般的建议 请教医生。 出示此安全技术说明书给到现场的医生看。 吸入 如果吸入,请将患者移到新鲜空气处。 如果停止了呼吸,给于人工呼吸。 请教医生。 皮肤接触 用肥皂和大量的水冲洗。 立即将患者送往医院。 请教医生。 眼睛接触 用水冲洗眼睛作为预防措施。 食入 切勿给失去知觉者从嘴里喂食任何东西。 用水漱口。 请教医生。 4.2 主要症状和影响，急性和迟发效应 4.3 及时的医疗处理和所需的特殊处理的说明和指示 无数据资料 模块5. 消防措施 5.1 灭火介质 灭火方法及灭火剂 用水雾,耐醇泡沫,干粉或二氧化碳灭火。 5.2 源于此物质或混合物的特别的危害 碳氧化物, 氮氧化物, 氯化氢气体 5.3 给消防员的建议 如必要的话,戴自给式呼吸器去救火。 5.4 进一步信息 无数据资料 模块6. 泄露应急处理 6.1 人员的预防,防护设备和紧急处理程序 戴呼吸罩。 防止粉尘的生成。 防止吸入蒸汽、气雾或气体。 保证充分的通风。 将人员撤离到安全区域。 避免吸入粉尘。 6.2 环境保护措施 在确保安全的前提下，采取措施防止进一步的泄漏或溢出。 不要让产物进入下水道。 6.3 抑制和清除溢出物的方法和材料 收集、处理泄漏物，不要产生灰尘。 扫掉和铲掉。 存放进适当的闭口容器中待处理。 6.4 参考其他部分 丢弃处理请参阅第13节。 模块7. 操作处置与储存 7.1 安全操作的注意事项 避免接触皮肤和眼睛。 防止粉尘和气溶胶生成。 在有粉尘生成的地方,提供合适的排风设备。 7.2 安全储存的条件,包括任何不兼容性 贮存在阴凉处。 容器保持紧闭，储存在干燥通风处。 7.3 特定用途 无数据资料 模块8. 接触控制和个体防护 8.1 容许浓度 最高容许浓度 没有已知的国家规定的暴露极限。 8.2 暴露控制 适当的技术控制 避免与皮肤、眼睛和衣服接触。 休息以前和操作过此产品之后立即洗手。 个体防护设备 眼/面保护 面罩與安全眼鏡请使用经官方标准如NIOSH (美国) 或 EN 166(欧盟) 检测与批准的设备防护眼部。 皮肤保护 戴手套取 手套在使用前必须受检查。 请使用合适的方法脱除手套(不要接触手套外部表面),避免任何皮肤部位接触此产品. 使用后请将被污染过的手套根据相关法律法规和有效的实验室规章程序谨慎处理. 请清洗并吹干双手 所选择的保护手套必须符合EU的89/686/EEC规定和从它衍生出来的EN 376标准。 身体保护 全套防化学试剂工作服, 防护设备的类型必须根据特定工作场所中的危险物的浓度和含量来选择。 呼吸系统防护 如危险性评测显示需要使用空气净化的防毒面具，请使用全面罩式多功能微粒防毒面具N100型（US ）或P3型（EN 143）防毒面具筒作为工程控制的候补。如果防毒面具是保护的唯一方式，则使用全面罩式送风防毒 面具。 呼吸器使用经过测试并通过政府标准如NIOSH（US）或CEN（EU）的呼吸器和零件。 模块9. 理化特性 9.1 基本的理化特性的信息 a) 外观与性状 形状: 粉末 颜色: 棕灰色 b) 气味 无数据资料 c) 气味阈值 无数据资料 d) pH值 无数据资料 e) 熔点/凝固点 155 °C f) 起始沸点和沸程 无数据资料 g) 闪点 无数据资料 h) 蒸发速率 无数据资料 i) 易燃性(固体,气体) 无数据资料 j) 高的/低的燃烧性或爆炸性限度 无数据资料 k) 蒸汽压 无数据资料 l) 蒸汽密度 无数据资料 m) 相对密度 无数据资料 n) 水溶性 无数据资料 o) n-辛醇/水分配系数 无数据资料 p) 自燃温度 无数据资料 q) 分解温度 无数据资料 r) 粘度 无数据资料 模块10. 稳定性和反应活性 10.1 反应性 无数据资料 10.2 稳定性 无数据资料 10.3 危险反应的可能性 无数据资料 10.4 应避免的条件 无数据资料 10.5 不兼容的材料 强碱 10.6 危险的分解产物 其它分解产物 - 无数据资料 模块11. 毒理学资料 11.1 毒理学影响的信息 急性毒性 半数致死剂量 (LD50) 经口 - 大鼠 - 2.42 mg/kg 备注: 胃肠的：胃溃疡或胃出血 皮肤刺激或腐蚀 无数据资料 眼睛刺激或腐蚀 无数据资料 呼吸道或皮肤过敏 无数据资料 生殖细胞突变性 细胞突变性-体外试验 - 大鼠 - 其他细胞类型 宿主介入的测试 细胞突变性-体内试验 - 大鼠 - 经口 显性致死实验 致癌性 IARC: 此产品中没有大于或等于 0。1%含量的组分被 IARC鉴别为可能的或肯定的人类致癌物。 生殖毒性 实验室试验表明有畸胎生成效应 特异性靶器官系统毒性（一次接触） 无数据资料 特异性靶器官系统毒性（反复接触） 无数据资料 吸入危险 无数据资料 潜在的健康影响 吸入吸入可能有害。 可能引起呼吸道刺激。 摄入如果服入了可能会致死。 皮肤如果通过皮肤吸收可能是有害的。 可能引起皮肤刺激。 眼睛可能引起眼睛刺激。 附加说明 化学物质毒性作用登记: 无数据资料 模块12. 生态学资料 12.1 生态毒性 无数据资料 12.2 持久存留性和降解性 无数据资料 12.3 潜在的生物蓄积性 无数据资料 12.4 土壤中的迁移性 无数据资料 12.5 PBT 和 vPvB的结果评价 无数据资料 12.6 其它不利的影响 无数据资料 模块13. 废弃处置 13.1 废物处理方法 产品 将剩余的和未回收的溶液交给处理公司。 与易燃溶剂相溶或者相混合，在备有燃烧后处理和洗刷作用的化学焚化炉中燃烧 受污染的容器和包装 作为未用过的产品弃置。 模块14. 运输信息 14.1 联合国危险货物编号 欧洲陆运危规: 2811国际海运危规: 2811国际空运危规: 2811 14.2 联合国（UN）规定的名称 欧洲陆运危规: TOXIC SOLID, ORGANIC, N.O.S. (Indometacin) 国际海运危规: TOXIC SOLID, ORGANIC, N.O.S. (Indometacin) 国际空运危规: Toxic solid, organic, n.o.s. (Indometacin) 14.3 运输危险类别 欧洲陆运危规: 6.1国际海运危规: 6.1国际空运危规: 6.1 14.4 包裹组 欧洲陆运危规: I国际海运危规: I国际空运危规: I 14.5 环境危险 欧洲陆运危规: 否国际海运危规 海运污染物: 否国际空运危规: 否 14.6 对使用者的特别提醒 无数据资料 模块 15 - 法规信息 N/A 模块16 - 其他信息 N/A

毒性和生态

CHEMICAL IDENTIFICATION RTECS NUMBER : NL3500000 CHEMICAL NAME : Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl- CAS REGISTRY NUMBER : 53-86-1 BEILSTEIN REFERENCE NO. : 0497341 LAST UPDATED : 199703 DATA ITEMS CITED : 125 MOLECULAR FORMULA : C19-H16-Cl-N-O4 MOLECULAR WEIGHT : 357.81 WISWESSER LINE NOTATION : T56 BNJ BVR CG& C1 D1VQ GO1 HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - man DOSE/DURATION : 4286 ug/kg/2D-I TOXIC EFFECTS : Skin and Appendages - dermatitis, other (after systemic exposure) TYPE OF TEST : LDLo - Lowest published lethal dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - man DOSE/DURATION : 15 mg/kg/2W-I TOXIC EFFECTS : Blood - aplastic anemia TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - infant DOSE/DURATION : 400 ug/kg/2D-I TOXIC EFFECTS : Gastrointestinal - necrotic changes TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - woman DOSE/DURATION : 2098 ug/kg/1D-I TOXIC EFFECTS : Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Kidney, Ureter, Bladder - urine volume decreased TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - man DOSE/DURATION : 22500 ug/kg/3W-I TOXIC EFFECTS : Liver - hepatitis, fibrous (cirrhosis, post-necrotic scarring) Liver - other changes TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human DOSE/DURATION : 113 mg/kg/8W-I TOXIC EFFECTS : Gastrointestinal - hypermotility, diarrhea Gastrointestinal - other changes TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Human - infant DOSE/DURATION : 200 ug/kg TOXIC EFFECTS : Blood - hemorrhage TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Unreported SPECIES OBSERVED : Human - man DOSE/DURATION : 499 mg/kg/87W-I TOXIC EFFECTS : Behavioral - stiffness Kidney, Ureter, Bladder - hematuria TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Rectal SPECIES OBSERVED : Human - man DOSE/DURATION : 2586 mg/kg/3.5Y-I TOXIC EFFECTS : Sense Organs and Special Senses (Eye) - retinal changes (pigmentary depositions, retinitis, other) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Multiple routes SPECIES OBSERVED : Human - man DOSE/DURATION : 3557 mg/kg/5Y-I TOXIC EFFECTS : Sense Organs and Special Senses (Eye) - retinal changes (pigmentary depositions, retinitis, other) TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 2420 ug/kg TOXIC EFFECTS : Gastrointestinal - ulceration or bleeding from stomach TYPE OF TEST : LD - Lethal dose ROUTE OF EXPOSURE : Administration onto the skin SPECIES OBSERVED : Rodent - rat DOSE/DURATION : >250 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 13 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 12 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 21 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intramuscular SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 26300 ug/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Rectal SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 31900 ug/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 11841 ug/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 10 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 18300 ug/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 30 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intramuscular SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 18200 ug/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Mammal - dog DOSE/DURATION : 160 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Mammal - dog DOSE/DURATION : 100 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Mammal - cat DOSE/DURATION : 320 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LDLo - Lowest published lethal dose ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Mammal - cat DOSE/DURATION : 20200 ug/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rabbit DOSE/DURATION : 135 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - guinea pig DOSE/DURATION : 100 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD - Lethal dose ROUTE OF EXPOSURE : Administration onto the skin SPECIES OBSERVED : Rodent - guinea pig DOSE/DURATION : >100 mg/kg TOXIC EFFECTS : Behavioral - excitement TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - guinea pig DOSE/DURATION : 143 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - guinea pig DOSE/DURATION : 180 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - hamster DOSE/DURATION : 81 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Mammal - species unspecified DOSE/DURATION : 8 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 33 mg/kg/11D-I TOXIC EFFECTS : Gastrointestinal - ulceration or bleeding from stomach Gastrointestinal - ulceration or bleeding from duodenum Gastrointestinal - other changes TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 168 mg/kg/4W-C TOXIC EFFECTS : Lungs, Thorax, or Respiration - changes in lung weight Endocrine - changes in spleen weight Blood - normocytic anemia TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 273 mg/kg/13W-I TOXIC EFFECTS : Blood - normocytic anemia Biochemical - Metabolism (Intermediary) - other proteins Related to Chronic Data - death TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 1820 mg/kg/52W-C TOXIC EFFECTS : Gastrointestinal - ulceration or bleeding from small intestine Nutritional and Gross Metabolic - weight loss or decreased weight gain Related to Chronic Data - death TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 210 mg/kg/35D-C TOXIC EFFECTS : Gastrointestinal - ulceration or bleeding from stomach Endocrine - other changes Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 650 mg/kg/26W-I TOXIC EFFECTS : Behavioral - food intake (animal) Gastrointestinal - ulceration or bleeding from small intestine Nutritional and Gross Metabolic - weight loss or decreased weight gain TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 105 mg/kg/21D-I TOXIC EFFECTS : Liver - changes in liver weight Kidney, Ureter, Bladder - changes in bladder weight Related to Chronic Data - changes in ovarian weight TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 24 mg/kg/4D-I TOXIC EFFECTS : Gastrointestinal - ulceration or bleeding from stomach TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 150 mg/kg/5W-I TOXIC EFFECTS : Lungs, Thorax, or Respiration - other changes Blood - changes in spleen Related to Chronic Data - death TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Mammal - dog DOSE/DURATION : 90 mg/kg/90D-C TOXIC EFFECTS : Gastrointestinal - ulceration or bleeding from stomach Gastrointestinal - ulceration or bleeding from small intestine Gastrointestinal - hypermotility, diarrhea TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Mammal - dog DOSE/DURATION : 350 mg/kg/5W-I TOXIC EFFECTS : Gastrointestinal - ulceration or bleeding from large intestine Kidney, Ureter, Bladder - other changes in urine composition Related to Chronic Data - death TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Primate - monkey DOSE/DURATION : 135 mg/kg/90D-C TOXIC EFFECTS : Gastrointestinal - ulceration or bleeding from stomach Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol) Blood - changes in leukocyte (WBC) count TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Mammal - species unspecified DOSE/DURATION : 168 mg/kg/4W-I TOXIC EFFECTS : Gastrointestinal - necrotic changes Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol) Nutritional and Gross Metabolic - changes in chlorine TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 644 mg/kg/92W-C TOXIC EFFECTS : Tumorigenic - neoplastic by RTECS criteria Skin and Appendages - tumors TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 1500 ug/kg SEX/DURATION : female 36 week(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - respiratory system Reproductive - Effects on Newborn - other neonatal measures or effects TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 1500 mg/kg SEX/DURATION : female 27 week(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 12 mg/kg SEX/DURATION : female 33-34 week(s) after conception TOXIC EFFECTS : Reproductive - Effects on Newborn - stillbirth TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 525 mg/kg SEX/DURATION : female 16-32 week(s) after conception TOXIC EFFECTS : Reproductive - Maternal Effects - parturition Reproductive - Maternal Effects - other effects Reproductive - Specific Developmental Abnormalities - urogenital system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous DOSE : 18 mg/kg SEX/DURATION : female 33-34 week(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - homeostasis TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Unreported DOSE : 6 mg/kg SEX/DURATION : female 39 week(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - urogenital system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Unreported DOSE : 4 mg/kg SEX/DURATION : female 10 week(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - urogenital system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Unreported DOSE : 2 mg/kg SEX/DURATION : female 28 week(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - urogenital system Reproductive - Specific Developmental Abnormalities - homeostasis TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Unreported DOSE : 12 mg/kg SEX/DURATION : female 32 week(s) after conception TOXIC EFFECTS : Reproductive - Effects on Newborn - stillbirth TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Unreported DOSE : 14 mg/kg SEX/DURATION : female 34 week(s) after conception TOXIC EFFECTS : Reproductive - Effects on Newborn - other neonatal measures or effects TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Multiple routes DOSE : 22 mg/kg SEX/DURATION : female 33 week(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Effects on Newborn - Apgar score (human only) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Rectal DOSE : 12 mg/kg SEX/DURATION : female 28 week(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - blood and lymphatic systems (including spleen and marrow) Reproductive - Specific Developmental Abnormalities - gastrointestinal system Reproductive - Specific Developmental Abnormalities - urogenital system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 1 mg/kg SEX/DURATION : female 21 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 300 ug/kg SEX/DURATION : female 21-22 day(s) after conception TOXIC EFFECTS : Reproductive - Maternal Effects - parturition Reproductive - Effects on Newborn - stillbirth Reproductive - Effects on Newborn - live birth index (measured after birth) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 10 mg/kg SEX/DURATION : female 17-22 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system Reproductive - Specific Developmental Abnormalities - respiratory system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 12 mg/kg SEX/DURATION : female 5-16 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 20 mg/kg SEX/DURATION : female 1-21 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - other developmental abnormalities TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal DOSE : 2500 ug/kg SEX/DURATION : female 1 day(s) pre-mating TOXIC EFFECTS : Reproductive - Fertility - other measures of fertility TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal DOSE : 28 mg/kg SEX/DURATION : male 7 day(s) pre-mating TOXIC EFFECTS : Reproductive - Fertility - male fertility index (e.g. # males impregnating females per # males exposed to fertile nonpregnant females) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal DOSE : 4150 ug/kg SEX/DURATION : female 1 day(s) pre-mating TOXIC EFFECTS : Reproductive - Fertility - other measures of fertility TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 5 mg/kg SEX/DURATION : female 5 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 2500 ug/kg SEX/DURATION : female 1 day(s) pre-mating TOXIC EFFECTS : Reproductive - Fertility - other measures of fertility TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 12 mg/kg SEX/DURATION : female 3-4 day(s) after conception TOXIC EFFECTS : Reproductive - Maternal Effects - uterus, cervix, vagina Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 9 mg/kg SEX/DURATION : female 9 day(s) pre-mating TOXIC EFFECTS : Reproductive - Maternal Effects - other effects TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Parenteral DOSE : 3 mg/kg SEX/DURATION : female 19-21 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system Reproductive - Specific Developmental Abnormalities - respiratory system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Unreported DOSE : 3 mg/kg SEX/DURATION : female 20 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intrauterine DOSE : 500 ug/kg SEX/DURATION : female 4 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravaginal DOSE : 125 mg/kg SEX/DURATION : female 7 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth) Reproductive - Fertility - other measures of fertility TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 10 mg/kg SEX/DURATION : female 7 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - eye/ear TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 10 mg/kg SEX/DURATION : female 7 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - musculoskeletal system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 4 mg/kg SEX/DURATION : female 13 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 9 mg/kg SEX/DURATION : female 2 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 40 mg/kg SEX/DURATION : female 8-15 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - body wall TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 40 mg/kg SEX/DURATION : female 8-15 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - musculoskeletal system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 8 mg/kg SEX/DURATION : female 1 day(s) pre-mating TOXIC EFFECTS : Reproductive - Maternal Effects - uterus, cervix, vagina Reproductive - Fertility - other measures of fertility TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Parenteral DOSE : 8 mg/kg SEX/DURATION : female 1 day(s) pre-mating TOXIC EFFECTS : Reproductive - Fertility - other measures of fertility TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 496 mg/kg SEX/DURATION : female 21-26 week(s) after conception TOXIC EFFECTS : Reproductive - Maternal Effects - parturition Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) Reproductive - Effects on Newborn - physical TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 747 mg/kg SEX/DURATION : female 21-26 week(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - extra-embryonic structures (e.g., placenta, umbilical cord) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 6 mg/kg SEX/DURATION : female 2 day(s) pre-mating TOXIC EFFECTS : Reproductive - Fertility - other measures of fertility TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 96 mg/kg SEX/DURATION : female 20-31 day(s) after conception TOXIC EFFECTS : Reproductive - Maternal Effects - parturition TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 10 mg/kg SEX/DURATION : female 29 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 6 mg/kg SEX/DURATION : female 2 day(s) pre-mating TOXIC EFFECTS : Reproductive - Fertility - other measures of fertility TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 1590 ug/kg SEX/DURATION : female 6 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - maternal-fetal exchange TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 48 mg/kg SEX/DURATION : female 23-28 day(s) after conception TOXIC EFFECTS : Reproductive - Maternal Effects - parturition TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 32 mg/kg SEX/DURATION : female 5-6 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 24 mg/kg SEX/DURATION : female 4-7 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - other measures of fertility Reproductive - Effects on Embryo or Fetus - extra-embryonic structures (e.g., placenta, umbilical cord) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 64 mg/kg SEX/DURATION : female 9-12 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 20 mg/kg SEX/DURATION : female 26-29 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous DOSE : 148 mg/kg SEX/DURATION : female 1-9 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous DOSE : 20 mg/kg SEX/DURATION : female 1 day(s) pre-mating TOXIC EFFECTS : Reproductive - Fertility - other measures of fertility TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous DOSE : 20 mg/kg SEX/DURATION : female 1 day(s) pre-mating TOXIC EFFECTS : Reproductive - Fertility - other measures of fertility TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 7500 ug/kg SEX/DURATION : female 1 day(s) pre-mating TOXIC EFFECTS : Reproductive - Fertility - other measures of fertility TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 5500 ug/kg SEX/DURATION : female 1-3 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 30 mg/kg SEX/DURATION : female 24-26 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - respiratory system Reproductive - Effects on Newborn - biochemical and metabolic TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Parenteral DOSE : 2500 ng/kg SEX/DURATION : female 1 day(s) pre-mating TOXIC EFFECTS : Reproductive - Fertility - other measures of fertility TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 160 mg/kg SEX/DURATION : female 16 day(s) pre-mating TOXIC EFFECTS : Reproductive - Fertility - other measures of fertility TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 240 mg/kg SEX/DURATION : female 12 day(s) pre-mating TOXIC EFFECTS : Reproductive - Maternal Effects - menstrual cycle changes or disorders TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intrauterine DOSE : 66640 ug/kg SEX/DURATION : female 9 day(s) pre-mating TOXIC EFFECTS : Reproductive - Maternal Effects - menstrual cycle changes or disorders TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 144 mg/kg SEX/DURATION : female 18 day(s) pre-mating TOXIC EFFECTS : Reproductive - Maternal Effects - other effects TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Unreported DOSE : 40 ug/kg SEX/DURATION : female 1 day(s) pre-mating TOXIC EFFECTS : Reproductive - Fertility - other measures of fertility TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 1 mg/kg SEX/DURATION : female 21 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system TYPE OF TEST : Mutation test systems - not otherwise specified TYPE OF TEST : Dominant lethal test TYPE OF TEST : Micronucleus test TYPE OF TEST : Micronucleus test TYPE OF TEST : DNA inhibition TYPE OF TEST : Cytogenetic analysis TYPE OF TEST : Sperm Morphology MUTATION DATA TEST SYSTEM : Rodent - mouse DOSE/DURATION : 60 mg/kg/5D (Continuous) REFERENCE : MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 188,343,1987 *** REVIEWS *** TOXICOLOGY REVIEW CTOXAO Clinical Toxicology. (New York, NY) V.1-18, 1968-81. For publisher information, see JTCTDW. Volume(issue)/page/year: 17,85,1980 TOXICOLOGY REVIEW REPTED Reproductive Toxicology. (Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523) V.1- 1987- Volume(issue)/page/year: 9,7,1995 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X4091 No. of Facilities: 123 (estimated) No. of Industries: 2 No. of Occupations: 10 No. of Employees: 5082 (estimated) No. of Female Employees: 2130 (estimated)

安全

• 符号: GHS06
• 信号词: Danger
• 危害声明: H300
• 警示性声明: Missing Phrase - N15.00950417
• 个人防护装备: Eyeshields;Faceshields;Gloves;type P2 (EN 143) respirator cartridges
• 危害码 (欧洲): T+:Verytoxic;
• 风险声明 (欧洲): R28
• 安全声明 (欧洲): S28-S36/37-S45
• 危险品运输编码: UN 2811 6.1/PG 1
• WGK德国: 3
• RTECS号: NL3500000
• 包装等级: I
• 危险类别: 6.1
• 海关编码: 2933290090

合成路线

上下游产品

上游产品  9
19501-58-7 122-01-0 123-76-2 24438-49-1
16401-99-3 17536-38-8 591-12-8 16390-07-1
873657-14-8
下游产品  10
261766-32-9 2504-32-7 23694-51-1 27035-30-9
2854-32-2 75523-11-4 53164-05-9 536-40-3
104425-42-5 1601-19-0

制备

对氨基苯甲醚经重氮化、还原、酸化、水解、环合，得到消炎痛。

海关

海关编码	2933990090
中文概述	2933990090. 其他仅含氮杂原子的杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%
申报要素	品名, 成分含量, 用途, 乌洛托品请注明外观, 6－己内酰胺请注明外观, 签约日期
Summary	2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%